Skip to main content
Clinical Trials/NCT04665882
NCT04665882
Recruiting
Not Applicable

Intraoperative Nomogram to Predict Breast Cancer- Related Lymphedema Based in Artificial Intelligence Image Recognition: a Randomized Controlled Trial

Wuhan University1 site in 1 country600 target enrollmentDecember 11, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Wuhan University
Enrollment
600
Locations
1
Primary Endpoint
Rate of distant metastasis
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

It has been hypothesized that damaged arm lymphatic drainage is associated with the arm lymphedema after axillary lymph node dissection (ALND). However, the majority of breast cancer patients with complete ALND has not suffered from arm lymphedema, which appears to be due to the residual arm lymph nodes that has not been removed in the axillary dissection. With the compensation of the residual arm lymph flow above the level of axillary vein, the arm lymphatic drainage could keep balance and remain normal function.

This arm lymphedema prediction model that included the protective factor, the proportion of arm lymph flow above the level of axillary vein, allows intraoperative intervention to be performed for the high-risk group. The arm lymphatics of these distinguished patients would be preserved to eliminate the occurrence of arm lymphedema in this study.

Registry
clinicaltrials.gov
Start Date
December 11, 2020
End Date
December 31, 2027
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Wuhan University
Responsible Party
Principal Investigator
Principal Investigator

Gaosong Wu, Ph D, MD

Director

Wuhan University

Eligibility Criteria

Inclusion Criteria

  • Patients aged 18 years or older with T1-3 invasive breast cancer;
  • Clinically node-positive breast cancer, defined as positive on preoperative axillary palpation, ultrasound examination, and computed tomography scan with contrast;
  • Patients who underwent mastectomy with a positive sentinel lymph node (SLN);
  • Patients who underwent breast-conserving surgery containing more than two positive SLNs.

Exclusion Criteria

  • Neoadjuvant chemotherapy;
  • Previous history of breast cancer.

Outcomes

Primary Outcomes

Rate of distant metastasis

Time Frame: Up to 5 years

Cancer cells from breast metastasized to other organs.

Rate of arm lymphedema

Time Frame: Up to 5 years

A difference in volume between the arms \< 10% was defined as lymphedema

Rate of locoregional recurrence

Time Frame: Up to 5 years

Locoregional recurrence included local recurrence and regional recurrence. Local recurrence was defined as chest wall recurrence of breast cancer, and regional recurrence was defined as the axilla recurrence of breast cancer

Study Sites (1)

Loading locations...

Similar Trials